Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia.
Fanconi anemia is a rare bone marrow failure and cancer predisposition syndrome. Childhood onset of aplastic anemia is one of the hallmarks of this condition. Supportive therapy in the form of blood products, androgens, and hematopoietic growth factors may boost blood counts temporarily. However, allogeneic hematopoietic stem cell transplantation (HSCT) currently remains the only curative treatment option for the hematologic manifestations of Fanconi anemia (FA). Here we review current clinical and pre-clinical strategies for treating hematopoietic stem cell (HSC) failure, including the experience with mobilizing and collecting CD34+ hematopoietic stem and progenitor cells as target cells for somatic gene therapy, the current state of FA gene therapy trials, and future prospects for cell and gene therapy.
Müller
Lars U W
LU
Department of Medicine, Division of Pediatric Hematology Oncology, Children's Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, United States.
Williams
David A
DA
D000818:Animals; D001855:Bone Marrow Diseases / Q000209:etiology; D064987:Cell- and Tissue-Based Therapy; D016207:Cytokines / Q000502:physiology; D005199:Fanconi Anemia / Q000235:genetics / Q000473:pathology / Q000628:therapy; D005544:Forecasting; D015316:Genetic Therapy; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation
D016207:Cytokines